FMS - Humacyte expands collaboration with Fresenius Medical Care

Humacyte, clinical-stage biotechnology platform company that is to be merged with SPAC Alpha Healthcare Acquisition Corp. (AHAC), announces the expansion of the strategic collaboration between Fresenius Medical Care (FMS).Under the expanded Distribution Agreement, Fresenius Medical Care to have the exclusive rights to commercialize Humacyte’s 6 millimeter x 42 centimeter human acellular vessel and all improvements thereto, and modifications and derivatives thereof (‘HAVs’) in vascular trauma outside of the United States.Related (Feb 17): Humacyte sets SPAC merger with Alpha Healthcare, valuing biotech at $1.1B

For further details see:

Humacyte expands collaboration with Fresenius Medical Care